Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TZ-POR 7c
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
TZ-POR 7c is a novel small molecule thiazolidinedione (TZD) derivative being investigated for the treatment of type 2 diabetes. Structurally derived from pioglitazone by the introduction of a pyrimidine moiety as an effector site, it functions as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist. The compound is designed to regulate glucose metabolism and enhance insulin sensitivity. Preclinical evaluations have demonstrated that TZ-POR 7c reduces basal insulin secretion by approximately 20% while increasing glucose-stimulated insulin secretion by 25% and promoting glucose uptake in target tissues compared to controls.
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on TZ-POR 7c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TZ-POR 7c.